{"denoms":[{"counts":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"310"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"BG000","title":"Pembrolizumab + Lenalidomide + Dexamethasone"},{"description":"Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"BG001","title":"Lenolidomide + Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.0","value":"74.4"},{"groupId":"BG001","spread":"5.9","value":"74.3"},{"groupId":"BG002","spread":"6.0","value":"74.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"166"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"144"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"279"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"23"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"54"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"236"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"92"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"136"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"80"}]}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Missing"}],"description":"The International Staging System (ISS) defines the factors that influence patient survival. The system has 3 stages based on the measurement of serum albumin and the levels of serum β2-microglobulin (β2-M).\n\nStage I: β2-M \\<3.5 mg/L with a serum albumin of 3.5 g/dL or more;\n\nStage II: Either of these 2 criteria:\n\nβ2-M between 3.5 mg/L and 5.5 mg/dL Albumin \\<3.5 g/dL; Stage III: β2-M \\>5.5 mg/L.","paramType":"NUMBER","title":"International Stage (I, II, III).","unitOfMeasure":"Participants"}],"populationDescription":"The analysis population included all randomized participants."}